Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia

Hypertension

Volumn 46, Issue 4, 2005, Pages 772-779

  Chade, Alejandro R ^a   Mushin, Oren P ^a   Zhu, Xiangyang ^a   Rodriguez Porcel, Martin ^a   Grande, Joseph P ^a   Textor, Stephen C ^a   Lerman, Amir ^a   Lerman, Lilach O ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Fibrosis; Hypercholesterolemia; Kidney; Oxidative stress; Remodeling

Indexed keywords

COLLAGEN TYPE 4; ENDOTHELIN; GELATIN; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HYPERCHOLESTEROLEMIA; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PARENCHYMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SWINE; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; CHOLESTEROL, DIETARY; COLLAGEN TYPE IV; DIET; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FIBROSIS; HYPERCHOLESTEROLEMIA; KIDNEY; OXIDATIVE STRESS; SWINE; TIME FACTORS;

EID: 31944449240     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000184250.37607.da     Document Type: Article

References (51)

1. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. J Am Med Assoc. 2003;290:898-904.
2. van der Meer IM, Iglesias del Sol A, Hak AE, Bots ML, Hofman A, Witteman JC. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam Study. Stroke. 2003;34:2374-2379.
3. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293-301.
4. Crook ED, Thallapureddy A, Migdal S, Flack JM, Greene EL, Salahudeen A, Tucker JK, Taylor HA Jr. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci. 2003;325:340-348.
5. Wilson SH, Chade AR, Feldstein A, Sawamura T, Napoli C, Lerman A, Lerman LO. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolemia. Nephrol Dial Transplant. 2003;18:703-709.
6. Chade AR, Best PJ, Rodriguez Porcel M, Herrmann J, Zhu X, Sawamura T, Napoli C, Lerman A, Lerman LO. Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int. 2003;64:962-969.
7. Chade AR, Rodriguez-Porcel M, Rippentrop SJ, Lerman A, Lerman LO. Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. Am J Hypertens. 2003;16:111-115.
8. Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, Romero JC, Napoli C, Lerman LO. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation. 2002;106:1165-1171.
9. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C, Sawamura T, Textor SC, Lerman A, Lerman LO. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:1295-1301.
10. Lerman L, Textor SC. Pathophysiology of ischemic nephropathy. Urol Clin North Am. 2001;28:793-803.
11. Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001;82:674-682.
12. Chade AR, Rodriguez Parcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A, Lerman LO. Antioxidant intervention blunts renal Injury in experimental renovascular disease. J Am Soc Nephrol. 2004;15:958-966.
13. Eddy AA. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int. 1996;50:1139-1149.
14. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis. 1995;26:152-161.
15. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290-301.
16. Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol. 2000;11:574-581.
17. Rodriguez-Porcel M, Krier JD, Lerman A, Sheedy PF II, Romero JC, Napoli C, Lerman LO. Combination of hypercholesterolemia and hypertension augments renal function abnormalities. Hypertension. 2001;37:774-780.
18. Stulak JM, Lerman A, Caccitolo JA, Wilson SH, Romero JC, Schaff HV, Porcel MR, Lerman LO. Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atherosclerosis. 2001;154:195-201.
19. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168-175.
20. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, Romero JC. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37:541-546.
21. Krier JD, Ritman EL, Bajzer Z, Romero JC, Lerman A, Lerman LO. Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol. 2001;281:F630-638.
22. Lerman LO, Schwartz RS, Grande JP, Sheedy PF, Romero JC. Noninvasive evaluation of a novel swine model of renal artery stenosis. J Am Soc Nephrol. 1999;10:1455-1465.
23. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, Lerman LO. Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol. 2005;16:1005-1012.
24. Zhu X, Rodriguez Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation. 2004;109:2109-2115.
25. Feldstein A, Krier JD, Sarafov MH, Lerman A, Best PJ, Wilson SH, Lerman LO. In vivo renal vascular and tubular function in experimental hypercholesterolemia. Hypertension. 1999;34:859-864.
26. Anonymous. US Renal Data System Annual Data Report. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003.
27. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int Suppl. 2000;75:S27-S31.
28. Minami M, Kume N, Kataoka H, Morimoto M, Hayashida K, Sawamura T, Masaki T, Kita T. Transforming growth factor-beta(1) increases the expression of lectin-like oxidized low-density lipoprotein receptor-1. Biochem Biophys Res Commun. 2000;272:357-361.
29. Watanabe T, Pakala R, Katagiri T, Benedict CR. Antioxidant N-acetylcysteine inhibits vasoactive agents-potentiated mitogenic effect of mildly oxidized LDL on vascular smooth muscle cells. Hypertens Res. 2002;25:311-315.
30. Locher R, Brandes RP, Vetter W, Barton M. Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. Hypertension. 2002;39:645-650.
31. Rueckschloss U, Duerrschmidt N, Morawietz H. NADPH oxidase in endothelial cells: impact on atherosclerosis. Antioxid Redox Signal. 2003;5:171-180.
32. Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol. 1999;12:33-40.
33. Matsunaga T, Hokari S, Koyama I, Harada T, Komoda T. NF-kappa B activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun. 2003;303:313-319.
34. Muroya T, Ihara Y, Ikeda S, Yasuoka C, Miyahara Y, Urata Y, Kondo T, Kohno S. Oxidative modulation of NF-kappaB signaling by oxidized low-density lipoprotein. Biochem Biophys Res Commun. 2003;309:900-905.
35. Ding G, van Goor H, Ricardo SD, Orlowski JM, Diamond JR. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int. 1997;51:147-154.
36. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13:2600-2610.
37. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature. 2003;425:577-584.
38. Cheng J, Grande JP. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood). 2002;227:943-956.
39. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331-5338.
40. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem. 1995;270:5872-5876.
41. Lelongt B, Legallicier B, Piedagnel R, Ronco PM. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr Opin Nephrol Hypertens. 2001;10:7-12.
42. Dworkin LD, Gong R, Tolbert E, Centracchio J, Yano N, Zanabli AR, Esparza A, Rifai A. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int. 2004;65:409-419.
43. Ferrans VJ. New insights into the world of matrix metalloproteinases. Circulation. 2002;105:405-407.
44. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001;107:929-934.
45. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem. 2000;275:32167-32173.
46. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, Ritman EL, Lerman A. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation. 2002;105:415-418.
47. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
48. Adamczak M, Gross ML, Amann K, Ritz E. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol. 2004;15:3063-3072.
49. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension. 2004;44:974-981.
50. Suganami T, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Sawai K, Hidaka S, Ebihara K, Tanaka T, Sugawara A, Kawachi H, Vinson C, Ogawa Y, Nakao K. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J. 2005;19:127-129.
51. Evans RG, Madden AC, Denton KM. Diversity of responses of renal cortical and medullary blood flow to vasoconstrictors in conscious rabbits. Acta Physiol Scand. 2000;169:297-308.